<DOC>
	<DOCNO>NCT00276133</DOCNO>
	<brief_summary>Small dense low-density lipoprotein ( LDL ) play important role cause glomerular injury conversion oxidatively modify form LDL . However , study evaluate effect antilipidemic agent LDL particle size renoprotective action hyperlipidemic patient non-diabetic nephropathy .</brief_summary>
	<brief_title>Effects Atorvastatin Versus Probucol Small Dense LDL</brief_title>
	<detailed_description>The study randomize crossover trial compare effect atorvastatin ( 10 mg/day ) probucol ( 500 mg/day ) 24 week 30 patient ( urinary albumin excretion 0.3â€“2.0 g/day , creatinine clearance &gt; 30 ml/min/1.73 m2 serum creatinine concentration &lt; 2 mg/L ) . Lipid parameter , mean LDL particle diameter , creatinine clearance , urinary albumin creatinine excretion ratio measure treatment period . It evaluate , first , whether atorvastatin probucol significantly reduce serum total cholesterol LDL cholesterol concentration , second , whether atorvastatin probucol significantly increase LDL particle size , third , whether significant difference urinary albumin/creatinine excretion ratio creatinine clearance observe group treatment .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Probucol</mesh_term>
	<criteria>Hyperlipidemic patient nondiabetic nephropathy Endocrinological , hematological hepatic disease Cerebral infarction hemorrhage Homozygous familial hypercholesterolemia Uncontrolled hypertension Myocardial infarction occur within previous 6 month Unstable angina Diabetic nephropathy Abnormal thyroid function Receiving steroid immunosuppressive agent</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>small dense LDL</keyword>
</DOC>